Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

Chemotherapy vs. Chemo Free in Indolent Non-Hodgkin Lymphoma - Can We Improve Outcomes With Emerging Agents?

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Nathan H. Fowler
October 18, 2019
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
8th Annual Houston Methodist Cancer Symposium

8th Annual Houston Methodist Cancer Symposium

Fri, Aug 7, 2020
Indy Hematology Review

17th Indy Hematology Review

Sat, Aug 15, 2020
The Asian Oncology Society 1st International Conference

The Asian Oncology Society 1st International Conference

Sun, Aug 16, 2020
Total Health Conferencing

2020 ASCO Virtual Direct™ Highlights - San Juan

Fri, Aug 7, 2020
10:24
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Double-Hit Lymphoma Diagnosis, Initial and Relapsed/Refractory Treatment...

Feat. K. Dunleavy
08:39
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Next Questions in Hodgkin Lymphoma: Brentuximab Vedotin/PD-1+AVD as Fron...

Feat. S. Ansell
12:53
KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Non Hodgkin Lymphoma Update : Polatuzumab Vedotin for R/R D...

Feat. M. Hoffmann
19:49
2018 Pan Pacific Lymphoma Conference

Cutaneous T-cell Lymphoma: Management of Transformed Mycosis Fungoides a...

Feat. Y. Kim
24:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

ASH December 2018- Lymphoma - Efficacy and Safety from ZUMA 1, JULIET an...

Feat. F. Locke
06:12
Indy Hematology Review

New Approaches in DLBCL

Feat. J. Leonard
30:08
City of Hope

Advances in Therapy in Cutaneous T Cell Lymphoma

Feat. C. Querfeld
15:41
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

PI3Ki's in Indolent Lymphoma: Overview of Approved Drugs, Trial Based Da...

Feat. A. Zelenetz
07:27
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Plasmablastic Lymphoma: Survival Analysis of a SEER Database (2010-2016)...

Feat. J. Florindez
16:04
Xth Eurasian Hematology-Oncology Congress

St-Petersburg Hematological Centre Experience on the Use of BMT in Relap...

Feat. N. Mikhailova
08:30
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Lymphomas: Brentuximab Vedotin vs. Pembrolizumab - W...

Feat. N. Mehta-Shah
22:53
Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020

2019 ASH Update on the First-Line Therapy in Follicular Lymphoma: Rituxi...

Feat. A. Zelenetz
13:41
Seattle Genetics

4-Year Follow-up Data in Stage III/IV cHL

12:35
Seattle Genetics

Importance of Requesting CD30 Expression Percentage for PTCL

Feat. F. Foss
15:50
Indy Hematology Review

Treatment Algorithm for DLBCL

Feat. J. Leonard
14:35
Seattle Genetics

Efficacy Data from a Trial in Frontline PTCL

Feat. F. Foss
10:47
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review

ASH 2019 Updates in Indolent NHL: EZH2 Inhibition & Lenalidomide Combina...

Feat. N. Fowler
12:54
Craig Portell

Untreated Follicular Lymphoma - Treatment Options for Patients with Earl...

12:38
Seattle Genetics

An Alternative Approach to PET-Adaptive Treatment in Advanced (or Stage ...

Feat. J. Tuscano
13:51
Seattle Genetics

2- and 3-Year Data from a Trial in cHL

Feat. S. Smith